Targeted Therapy Treatment Innovations in AML - Episode 6

Part 1: Practical Considerations For Venetoclax in AML

Alexandra S. Wolff, PharmD, BCOP, highlights considerations for optimal use of venetoclax in patients with AML, such as tumor lysis syndrome prophylaxis.

EP. 1: Role of First Generation FLT3 Inhibitors in AML
EP. 2: Role of Second Generation FLT3 Inhibitors in AML
EP. 3: Part 1: IDH1 & IDH2 Inhibitors In Newly Diagnosed AML
EP. 4: Part 2: IDH1 & IDH2 Inhibitors In Newly Diagnosed AML
EP. 5: Role of Venetoclax in Treatment of AML
Now Viewing
EP. 6: Part 1: Practical Considerations For Venetoclax in AML
EP. 7: Part 2: Practical Considerations For Venetoclax in AML
EP. 8: 5-Year Follow-Up Data For CPX-351 in AML
EP. 9: CPX-351 in Clinical Practice For AML